In another clinical trial, 16 patients with R/R MM were treated with BCMA/CD38 bispecific CAR-T cells, and 14 of them had clinical response and 13 of them achieved CR after a median follow-up of 11.5 months (31). Here, CD38 is linked to Miyoshi myopathy.